RESUMEN
Unlike peripheral nerves, axonal regeneration is limited following injury to the spinal cord. While there may be reduced regenerative potential of injured neurons, the central nervous system (CNS) white matter environment appears to be more significant in limiting regrowth. Several factors may inhibit regeneration, and their neutralization can modestly enhance regrowth. However, most investigations have not considered the cytoarchitecture of spinal cord white matter. Several lines of investigation demonstrate that axonal regeneration is enhanced by maintaining, repairing, or reconstituting the parallel geometry of the spinal cord white matter. In this review, we focus on environmental factors that have been implicated as putative inhibitors of axonal regeneration and the evidence that their organization may be an important determinant in whether they inhibit or promote regeneration. Consideration of tissue geometry may be important for developing successful strategies to promote spinal cord regeneration.
Asunto(s)
Traumatismos de la Médula Espinal , Regeneración de la Medula Espinal , Axones/fisiología , Humanos , Regeneración Nerviosa/fisiología , Neuronas/fisiología , Médula Espinal , Traumatismos de la Médula Espinal/terapiaRESUMEN
Explants of embryonic chick sympathetic and sensory ganglia were found to exhibit asymmetric radial outgrowth of neurites under standard culture conditions with or without exogenous Nerve Growth Factor [NGF]. Opposing sides of an explant exhibited: a) differences in neurite length and, b) differences in neurite morphology. Strikingly, this asymmetry exhibited co-orientation among segregated, neighboring explants. The underlying mechanism(s) of the asymmetry and its co-orientation are not known but appear to depend on cell clustering because dissociated sympathetic neurons do not exhibit co-orientation whereas re-aggregated clusters of cells do. This emergent behavior may be similar to the community effect described in other cell types. If a similar phenomenon exists in the embryo, or in maturity, it may contribute to the establishment of proper orientation of neurite outgrowth during development and/or injury-induced neuronal plasticity.
Asunto(s)
Ganglios Sensoriales/citología , Proyección Neuronal , Cultivo Primario de Células/métodos , Técnicas de Cultivo de Tejidos/métodos , Animales , Embrión de PolloRESUMEN
In order to evaluate the contribution of substrate-bound factors to the extent and patterning of the sympathetic innervation of rat uterus following estrogen treatment, superior cervical ganglion explants from neonatal and adult ovariectomized rats were cultured on tissue sections of fresh frozen uterus from adult ovariectomized rats treated with estrogen or a vehicle. The main findings were: (1) neurite growth was greatly influenced by histological features of the underlying section; (2) on myometrial sections, neurites followed the orientation of the main axis of the longitudinally sectioned muscle cells; (3) neurites showed limited growth on transversally sectioned smooth muscle; (4) neuritic patterning was unaffected by a reduction in migrating ganglionic non-neuronal cells; (5) neurite outgrowth, but not non-neural cell migration, was markedly reduced on myometrial sections from rats treated with estrogen. These results suggest that adult myometrium continues to provide signals allowing the organotypic patterning and growth of sympathetic axons, that estrogen treatment modifies myometrial substrate properties so that it is less supportive for sympathetic neurite growth, and that adult sympathetic neurons retain their ability to recognize substrate-bound cues present in the myometrium. On endometrial sections, neurites formed radially symmetric halos, which were reduced in size on estrogen-treated endometrial substrates. Thus, changes in the neuritogenic capacity of the uterus underlie plasticity in uterine sympathetic nerves, and alterations in substrate-bound factors contribute to the diminished receptivity of the estrogenized uterus to its sympathetic innervation.
Asunto(s)
Estrógenos/farmacología , Neuritas/efectos de los fármacos , Neuritas/metabolismo , Sistema Nervioso Simpático/metabolismo , Útero/efectos de los fármacos , Útero/inervación , Animales , Movimiento Celular/efectos de los fármacos , Endometrio/citología , Endometrio/efectos de los fármacos , Endometrio/metabolismo , Femenino , Miometrio/citología , Miometrio/efectos de los fármacos , Miometrio/metabolismo , Ovariectomía , Ratas , Ratas Wistar , Sistema Nervioso Simpático/citología , Sistema Nervioso Simpático/efectos de los fármacos , Útero/citologíaRESUMEN
There is conflicting evidence regarding a possible association between the apolipoprotein E4 (APOE4) allele and the consequences of traumatic brain injury (TBI). Our aim was to carry out a meta-analysis of cohort studies of sufficient rigor to determine whether the presence of the APOE4 allele contributes to initial injury severity and/or poor outcome following TBI. MEDLINE, EMBase, CBMdisc, and CNKI databases were searched for literature published from January 1993 to October 2007. Of the 100 identified studies, 14 cohort studies were selected for analysis based on comprehensive quality assessment using a standardized scale. Data from the 14 eligible cohort studies included a total of 2527 participants, 736 with and 1791 without the APOE4 allele. The APOE4 allele was not associated with initial injury severity of TBI. The pooled RR were 1.11 (95% confidence interval [CI], 0.91 to 1.35) for severe injury, 1.06 (95% CI, 0.86-1.31) for moderate injury and 0.93 (95% CI, 0.81-1.06) for mild injury. However, the APOE4 allele was significantly associated with a poor outcome of TBI at 6 months after injury (RR = 1.36; 95% CI, 1.04-1.78). The association remained significant in sensitivity tests. This meta-analysis indicates that the presence of the APOE4 allele is not associated with the initial severity of brain injury following TBI but is associated with increased risk of poor long-term outcome at 6 months after injury.
Asunto(s)
Apolipoproteína E4/genética , Lesiones Encefálicas/diagnóstico , Lesiones Encefálicas/genética , Genotipo , Escala de Consecuencias de Glasgow , Humanos , Valor Predictivo de las Pruebas , PronósticoRESUMEN
A refined battery of neurological tests, SNAP (Simple Neuroassessment of Asymmetric Impairment), was developed and validated to efficiently assess neurological deficits induced in a mouse model of traumatic brain injury. Four to 7-month old mice were subjected to unilateral controlled cortical impact or sham injury (craniectomy only). Several behavioral tests (SNAP, beam walk, foot fault, and water maze) were used to assess functional deficits. SNAP was unique among these in that it required no expensive equipment and was performed in less than 5 min per mouse. SNAP demonstrated a high level of sensitivity and specificity as determined by receiver-operator characteristics curve analysis. Interrater reliability was good, as determined by Cohen's Kappa method and by comparing the sensitivity and specificity across various raters. SNAP detected deficits in proprioception, visual fields, and motor strength in brain-injured mice at 3 days, and was sensitive enough to detect magnitude and recovery of injury. The contribution of individual battery components changed as a function of time after injury, however, each was important to the overall SNAP score. SNAP provided a sensitive, reliable, time-efficient and cost-effective means of assessing neurological deficits in mice after unilateral brain injury.
Asunto(s)
Lesiones Encefálicas/psicología , Corteza Cerebral/lesiones , Animales , Conducta Animal/fisiología , Lesiones Encefálicas/genética , Lesiones Encefálicas/patología , Corteza Cerebral/patología , Enfermedad Crónica , Interpretación Estadística de Datos , Lateralidad Funcional/fisiología , Genotipo , Fuerza de la Mano/fisiología , Aprendizaje por Laberinto/fisiología , Ratones , Ratones Endogámicos C57BL , Examen Neurológico , Variaciones Dependientes del Observador , Equilibrio Postural/fisiología , Desempeño Psicomotor/fisiología , Reproducibilidad de los Resultados , Grabación de Cinta de VideoRESUMEN
Axonal regeneration is normally limited after injuries to CNS white matter. Infusion of neurotrophins has been successful in promoting regenerative growth through injured white matter but this growth generally fails to extend beyond the infusion site. These observations are consistent with a chemotropic effect of these factors on axonal growth and support the prevailing view that neurotrophin-induced axonal regeneration requires the use of gradients, i.e., gradually increasing neurotrophin levels along the target fiber tract. To examine the potential of global overexpression of neurotrophins to promote, and/or modify the orientation of, regenerative axonal growth within white matter, we grafted nerve growth factor (NGF) responsive neurons into the corpus callosum of transgenic mice overexpressing NGF throughout the CNS under control of the promoter for glial fibrillary acidic protein. One week later, glial fibrillary acidic protein and chondroitin sulfate proteoglycan immunoreactivity increased within injured white matter around the grafts. NGF levels were significantly higher in the brains of transgenic compared with non-transgenic mice and further elevated within injury sites compared with the homotypic region of the non-injured side. Although there was minimal outgrowth from neurons grafted into non-transgenic mice, extensive parallel axonal regeneration had occurred within the corpus callosum up to 1.5 mm beyond the astrogliotic scar (the site of maximum NGF expression) in transgenic mice. These results demonstrate that global overexpression of neurotrophins does not override the constraints limiting regenerative growth to parallel orientations and suggest that such factors need not be presented as positive gradients to promote axonal regeneration within white matter.
Asunto(s)
Sistema Nervioso Central/metabolismo , Conos de Crecimiento/metabolismo , Fibras Nerviosas Mielínicas/metabolismo , Factor de Crecimiento Nervioso/metabolismo , Regeneración Nerviosa/fisiología , Fibras Simpáticas Posganglionares/metabolismo , Animales , Astrocitos/citología , Astrocitos/fisiología , Axotomía , Lesiones Encefálicas/metabolismo , Lesiones Encefálicas/fisiopatología , Lesiones Encefálicas/terapia , Lesión Encefálica Crónica/metabolismo , Lesión Encefálica Crónica/fisiopatología , Lesión Encefálica Crónica/terapia , Sistema Nervioso Central/citología , Proteoglicanos Tipo Condroitín Sulfato/metabolismo , Cicatriz/fisiopatología , Cicatriz/prevención & control , Proteína Ácida Fibrilar de la Glía/genética , Proteína Ácida Fibrilar de la Glía/metabolismo , Supervivencia de Injerto/fisiología , Conos de Crecimiento/ultraestructura , Ratones , Ratones Transgénicos , Fibras Nerviosas Mielínicas/ultraestructura , Factor de Crecimiento Nervioso/genética , Regiones Promotoras Genéticas/genética , Ganglio Cervical Superior/citología , Ganglio Cervical Superior/metabolismo , Ganglio Cervical Superior/trasplante , Fibras Simpáticas Posganglionares/citología , Fibras Simpáticas Posganglionares/trasplante , Trasplante de Tejidos , Regulación hacia Arriba/fisiologíaRESUMEN
Under normal conditions, expression of the p75 neurotrophin receptor (p75NTR) by sympathetic neurons can increase the affinity of the signaling receptor, trkA, to target-derived nerve growth factor (NGF) at distal axons. We have previously reported that sprouting of sympathetic axons into NGF-rich target tissues is enhanced when p75NTR expression is perturbed, leading to the postulate that p75NTR may restrain sympathetic sprouting in response to elevated NGF levels. These observations were made using mice having a null mutation of the third p75NTR exon, a line that may express a hypomorphic form of this receptor. Since mice carrying a null mutation of the fourth p75NTR exon may not express a similar splice variant, we sought to determine whether these animals possess the same phenotype of enhanced sympathetic sprouting in response to elevated levels of NGF. Both lines of transgenic mice lacking p75NTR displayed similar degrees of sympathetic axonal sprouting into the cerebellum and trigeminal ganglia, two target tissues having elevated levels of NGF protein. Furthermore, the densities of sympathetic axons in both targets were significantly greater than those observed in age-matched NGF transgenic siblings expressing full-length p75NTR. Our new findings provide a comparative analysis of the phenotype in two independent mutations of the same neurotrophin receptor, revealing that p75NTR plays an important role in restricting sympathetic sprouting in response to higher NGF levels.
Asunto(s)
Exones/genética , Mutación , Factor de Crecimiento Nervioso/metabolismo , Neuritas/fisiología , Neuronas/citología , Receptor de Factor de Crecimiento Nervioso/genética , Sistema Nervioso Simpático/citología , Animales , Recuento de Células/métodos , Aumento de la Célula , Cerebelo/citología , Cerebelo/metabolismo , Ensayo de Inmunoadsorción Enzimática/métodos , Inmunohistoquímica/métodos , Ratones , Ratones Noqueados , Neuropéptido Y/metabolismo , Receptor de Factor de Crecimiento Nervioso/deficiencia , Receptor trkA/metabolismo , Ganglio Cervical Superior/citología , Ganglio Cervical Superior/metabolismo , Sistema Nervioso Simpático/metabolismo , Ganglio del Trigémino/citología , Ganglio del Trigémino/metabolismo , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
BACKGROUND: The APOE genotype has a uniquely strong influence on the outcome of viral infection. The mechanism is unknown, although one possibility is direct inhibition of viral entry into cells. METHODS: We have examined the direct anti-infective activity of a peptide analogue of the receptor-binding region of apolipoprotein E (apoE) that is known as "apoE dimer tandem repeat peptide" (apoEdp) and has previously been shown to mimic some of the biological effects of apoE and that recently was shown to bind low-density lipoprotein receptor-related protein. RESULTS: apoEdp has activity against herpes simplex virus types 1 and 2, human immunodeficiency virus, Pseudomonas aeruginosa, and Staphylococcus aureus; concentrations in the range of 1-20 micromol/L inhibit infection by 50%. These biological actions depend on adoption of an alpha -helical structure, as has been found for other biological effects of apoE peptides. The peptide interferes with the earliest stages of viral infection, preventing viral attachment and exerting a mild virucidal action. In addition, an N-terminal fragment of apoE that also contains this binding domain has antiviral activity. CONCLUSIONS: These data suggest that human apoE or fragments containing the receptor-binding domain may contribute to innate immunity to viral infection by direct disruption of viral particles and/or inhibition of viral attachment, thus reducing viral entry.
Asunto(s)
Antiinfecciosos/farmacología , Apolipoproteínas E/química , Apolipoproteínas E/farmacología , Fragmentos de Péptidos/farmacología , Receptores de Lipoproteína/metabolismo , Animales , Apolipoproteínas E/metabolismo , Línea Celular , Chlorocebus aethiops , VIH-1/efectos de los fármacos , VIH-1/patogenicidad , Herpesvirus Humano 1/efectos de los fármacos , Herpesvirus Humano 1/patogenicidad , Herpesvirus Humano 2/efectos de los fármacos , Herpesvirus Humano 2/patogenicidad , Humanos , Pseudomonas aeruginosa/efectos de los fármacos , Staphylococcus aureus/efectos de los fármacos , Células VeroRESUMEN
The classic neurotrophin hypothesis is based on the idea that innervating neurons derive 'mature' neurotrophin provided by the target for their survival. Yet large precursor forms of the neurotrophin nerve growth factor (NGF) have been reported in both central and peripheral tissues. In the present study, immunoblotting was used to survey peripheral tissues containing NGF-responsive neurons and to characterize various NGF species. These results demonstrate that 'mature' forms of NGF, i.e., the 13 and 16kDa species, are rare in sympathetic and sensory ganglia and in their peripheral targets, and that large molecular weight NGF precursors are abundant. In addition, certain NGF forms predominate in a given tissue, with each tissue exhibiting a characteristic NGF expression pattern. These findings suggest that NGF processing in peripheral tissues and in NGF-responsive ganglia may involve a variety of NGF species.
Asunto(s)
Regulación de la Expresión Génica/fisiología , Factor de Crecimiento Nervioso/metabolismo , Ganglio Cervical Superior/metabolismo , Ganglio del Trigémino/metabolismo , Animales , Western Blotting/métodos , Corteza Cerebral/metabolismo , Femenino , Precursores de Proteínas/metabolismo , Ratas , Ratas Endogámicas F344RESUMEN
Apolipoprotein E (apoE) genotype is the single most important genetic risk factor for the most common (sporadic) form of Alzheimer's disease (AD). Increasing evidence supports the hypothesis that the presence of the E4 isoform of this cholesterol-binding protein contributes directly to disease risk, age of onset, and severity of the neuropathology. For example, studies in transgenic mice demonstrate that apoE is necessary for the formation of plaques with neuritic pathology. The precise mechanism by which apoE contributes to the disease remains unknown. However, several lines of investigation from a number of laboratories now point to a role for proteolytic fragments of apoE in the formation of both plaques and tangles, the two pathological hallmarks of the disease. In particular, the C-terminal portion of apoE has been implicated in binding to amyloid and is localized to plaques. The N-terminal domain, on the other hand, is neurotoxic in culture and has been localized to, and implicated in the formation of, neurofibrillary tangles. These results suggest that inhibition of apoE proteolysis is a potential therapeutic strategy for AD. Using human brain homogenates, we have determined that proteolysis of apoE is greatest at acidic pH and can be inhibited by compounds targeting aspartic proteases. The feasibility of screening candidate inhibitors is supported by both ELISA and immunoblotting methods. Future studies will use a combination of in vitro and in vivo assays to test the efficacy of the most effective compounds for their ability to inhibit apoE proteolysis in human brain and apoE transgenic mouse brain tissue.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/enzimología , Apolipoproteínas E/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Péptido Hidrolasas/efectos de los fármacos , Enfermedad de Alzheimer/genética , Animales , Apolipoproteínas E/genética , Encéfalo/fisiopatología , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Humanos , Ovillos Neurofibrilares/enzimología , Ovillos Neurofibrilares/genética , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/toxicidad , Péptido Hidrolasas/metabolismo , Placa Amiloide/enzimología , Placa Amiloide/genéticaRESUMEN
There is now a large body of evidence suggesting that apolipoprotein E (apoE) genotype is the single most important genetic risk factor for the most common (sporadic) form of Alzheimer's disease. Yet in proportion to the total number of investigations in this field, relatively few groups are studying the contribution of this cholesterol-binding protein to disease risk and severity. Of those that are, a major focus is on the impact of apoE on amyloid-related mechanisms of disease. I argue here that apoE should be considered a major culprit in its own right, not simply in a supporting role. The argument is based on several lines of evidence, including the fact that apoE is associated with both plaques and tangles, the overwhelming evidence for genetic risk of the disease attributed to apoE, increasing evidence that apoE might also modify risk of other nonamyloidogenic neurological diseases, neurotoxicity attributed to apoE and/or proteolytic fragments of apoE, negative consequences of transgenic expression of apoE4 in mice, and genetic evidence for polymorphisms that increase both apoE expression and disease risk, regardless of isoform.
Asunto(s)
Enfermedad de Alzheimer/genética , Apolipoproteínas E/genética , Enfermedad de Alzheimer/patología , Animales , Apolipoproteína E4 , Humanos , Ratones , Ratones Transgénicos , Enfermedades del Sistema Nervioso/genética , Ovillos Neurofibrilares/patología , Factores de RiesgoRESUMEN
Apolipoprotein E (apoE) remains the most important genetic risk factor for the development of Alzheimer's disease (AD). Still elusive, the role of apoE is under intense investigation. We propose that proteolysis of apoE in the brain leads to two major fragments, N- and C-terminal apoE, each of which would drive a different neuropathological pathway. N-terminal fragments of apoE are implicated in neurotoxicity, and C-terminal fragments might play a role in amyloid deposition and plaque formation. The greater risk of AD associated with the E4 isoform might relate to its greater neurotoxicity. Drugs that either directly inhibit the toxic effects of apoE or prevent the production of apoE fragments may provide novel therapeutic approaches to the treatment of AD and other disorders in which apoE is implicated.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Apolipoproteínas E/antagonistas & inhibidores , Encéfalo/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Fragmentos de Péptidos/antagonistas & inhibidores , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/fisiopatología , Apolipoproteínas E/metabolismo , Encéfalo/metabolismo , Encéfalo/fisiopatología , Humanos , Ovillos Neurofibrilares/efectos de los fármacos , Ovillos Neurofibrilares/metabolismo , Fármacos Neuroprotectores/química , Neurotoxinas/antagonistas & inhibidores , Neurotoxinas/metabolismo , Fragmentos de Péptidos/metabolismo , Péptido Hidrolasas/efectos de los fármacos , Péptido Hidrolasas/metabolismo , Placa Amiloide/efectos de los fármacos , Placa Amiloide/metabolismo , Estructura Terciaria de Proteína/efectos de los fármacos , Estructura Terciaria de Proteína/fisiologíaAsunto(s)
Enfermedad de Alzheimer/patología , Apolipoproteínas E/metabolismo , Enfermedad de Alzheimer/genética , Animales , Apolipoproteína E3 , Apolipoproteína E4 , Apolipoproteínas E/genética , Astrocitos/patología , Encéfalo/patología , Expresión Génica/fisiología , Humanos , Ratones , Ratones Transgénicos , Neuronas/patologíaRESUMEN
Apolipoprotein E (apoE) has been genetically linked to late-onset Alzheimer's disease (AD). The role of this lipid-transport protein in AD remains to be established. One hypothesis is that apoE, particularly the apoE4 isoform, may have neurotoxic effects as demonstrated using apoE-related synthetic peptides and the N-terminal fragment of apoE. ApoE is a heparan-sulfate binding protein, and apoE peptide neurotoxicity can be blocked by heparin and prevented by degrading heparan sulfate or inhibiting its biosynthesis. The possibility that heparin inhibition of toxicity is mediated by a specific oligosaccharide sequence was investigated using a bioassay to determine the inhibition of apoE peptide toxicity by glycosaminoglycans and purified glycosaminoglycan oligosaccharides. Studies on modified heparins showed that the presence of N-sulfo groups and either 2- or 6-O sulfo groups were required for inhibition of toxicity. Heparin oligosaccharides with eight or more saccharide residues with seven O-sulfo groups and four N-sulfo groups exhibited potent inhibition. Larger oligosaccharides, and heparin and heparan sulfate polymers, afforded comparable, or somewhat better, protective effects but also caused clumping and detachment of cells when administrated alone.
Asunto(s)
Apolipoproteínas E/antagonistas & inhibidores , Apolipoproteínas E/toxicidad , Glicosaminoglicanos/farmacología , Neuronas/efectos de los fármacos , Oligosacáridos/farmacología , Animales , Apolipoproteínas E/metabolismo , Unión Competitiva/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Células Cultivadas , Embrión de Pollo , Dermatán Sulfato/metabolismo , Dermatán Sulfato/farmacología , Ganglios Simpáticos/citología , Ganglios Simpáticos/efectos de los fármacos , Ganglios Simpáticos/metabolismo , Glicosaminoglicanos/metabolismo , Proteoglicanos de Heparán Sulfato/metabolismo , Proteoglicanos de Heparán Sulfato/farmacología , Heparina/metabolismo , Heparina/farmacología , Heparina de Bajo-Peso-Molecular/metabolismo , Heparina de Bajo-Peso-Molecular/farmacología , Neuronas/metabolismo , Oligosacáridos/metabolismo , Tiempo de Tromboplastina Parcial , Unión Proteica/efectos de los fármacos , PorcinosRESUMEN
In spite of many well-documented examples of age-related reductions in neuronal plasticity, the causes of such changes remain largely unknown. One example of age-reduced plasticity involves an aberrant sprouting response of mature rat sympathetic neurons into the CNS (hippocampal formation). This phenomenon has proven to be useful for exploring the relative contribution of target aging (extrinsic influences) versus neuronal aging (intrinsic influences) to reduced sprouting. Aged sympathetic neurons mount a robust growth response when confronted with young target tissue or when exposed to exogenous trophic factor in vivo. In contrast, the aged target tissue (the hippocampal formation in this example) exhibits reduced receptivity for sympathetic sprouting. This change in the target does not appear to be due to alterations in baseline levels of trophic or substrate support for axonal growth. Rather, aging appears to dampen the consequences of target denervation so that the aged target elicits less sprouting. Age-related reductions in neuronal sprouting are speculated to reflect increasing commitment to information storage at the expense of neuronal plasticity.